As we all know by now, whenever there’s a financial crisis, healthy financial institutions often swoop in – either voluntarily or with some arm-twisting from regulators – to acquire distressed institutions. In light of the circumstances that give rise to these deals, it’s not surprising that they often give rise to some rather extraordinary disclosures or a lot of controversy over what isn’t disclosed.
UBS’s pending deal to acquire Credit Suisse is no exception. In fact, one of the risk factors identified in UBS’s recent F-4 filing for the deal can be fairly paraphrased as saying that “we were leaned on by the Swiss government to do this deal and didn’t have time for full due diligence.” Here’s the risk factor:
There is a risk that the short time frame and emergency circumstances of the due diligence UBS Group AG conducted of Credit Suisse limited UBS Group AG’s ability to thoroughly evaluate Credit Suisse and fully plan for its financial condition and associated liabilities. As described in more detail in the section entitled “The Merger—Background and Reasons for the Transaction” of this prospectus beginning on page 39, UBS Group AG was approached by Swiss governmental authorities on May 15, 2023 as the Swiss governmental authorities were considering whether to initiate resolution of Credit Suisse. To calm markets and avoid the possibility of contagion in the financial system, the Swiss government had determined that a decision would need to be made before the opening of markets following the weekend.
Therefore, UBS Group AG had until March 19, 2023 to conduct limited but intensive due diligence before deciding whether to enter into a merger agreement for the acquisition of Credit Suisse. Under the merger agreement, upon completion of the transaction, all liabilities of Credit Suisse will become liabilities of UBS Group AG. If the circumstances of the due diligence affected UBS Group AG’s ability to thoroughly consider Credit Suisse’s liabilities and weaknesses, it is possible that UBS Group AG will have agreed to a rescue that is considerably more difficult and risky than it had contemplated. This could affect the future performance of UBS Group AG, its share price, and its value as an enterprise.
This disclosure has caught the eye of the media, and it’s undoubtedly caught the eye of UBS’s stockholders as well. But that’s less of an issue for the deal itself than might otherwise be the case – because there’s another interesting disclosure in UBS’s Form F-4:
Pursuant to the Special Ordinance, the transaction will be implemented without the need for the approval of UBS Group AG shareholders or Credit Suisse shareholders. Therefore, there will be no Credit Suisse shareholders meeting or UBS Group AG shareholders meeting for purposes of voting on the approval of the merger agreement or the transaction and your vote is not required in connection with the transaction.
VC Glasscock recently issued the seventh memorandum opinion in the litigation involving Oracle’s 2016 acquisition of NetSuite, which John has blogged about here previously. In this derivative matter, the plaintiff stockholders argue that Oracle overpaid for NetSuite, alleging that Larry Ellison, founder, director and officer of Oracle who owned a large percentage of NetSuite, was a conflicted controller and the entire fairness standard should apply. In the latest, now post-trial, decision in In re Oracle Corp. Derivative Litig., (Del. Ch.; 5/23), VC Glasscock finds that while Ellison had the potential to control the transaction, he had neither actual control through stock ownership nor did he exercise actual control over the process. In fact, he scrupulously avoided it.
Ellison was not a majority stockholder and, while as a director, officer (but not CEO) and founder, he exerted significant influence, enough to survive the pleading stage, the facts at trial did not support the claim that he controlled the company or the transaction. VC Glasscock noted multiple instances of the board and Oracle’s co-CEOs giving thought to, but sometimes acting against, Ellison’s input, that Ellison did not propose the NetSuite acquisition and the hard-line negotiating position taken by the special transaction committee. Here’s an excerpt from the opinion:
Ellison is a force at Oracle, no doubt; he is the main creative party and a face of the company. I acknowledge that it is plausible that Ellison could have influenced the directors’ decision here, had he made an effort to do so, which he did not. The concept that an individual—without voting control of an entity, who does not generally control the entity, and who absents himself from a conflicted transaction—is subject to entire fairness review as a fiduciary solely because he is a respected figure with a potential to assert influence over the directors, is not Delaware law, as I understand it.
… To exercise actual control such that a minority stockholder is deemed a controller, she must “exercise[] such formidable voting and managerial power that, as a practical matter, [she] is no differently situated than if [she] had majority voting control.” In wielding such power, a minority stockholder deemed controller can “either (i) control . . . the corporation’s business and affairs in general or (ii) control . . . the corporation specifically for purposes of the challenged transaction.” Because I have found neither, under this understanding, Ellison was not a controller and business judgment applies.
This opinion is a good read for anyone facing a possible conflicted controller transaction. Oracle ran a tight process controlled by the special committee, where Ellison recused himself (on both sides of the transaction) and received—and followed—detailed rules of recusal approved by the committee, which prohibited Ellison from discussing the transaction with anyone but the committee, informed employees assessing the transaction about his recusal and forbade Oracle officers and employees from participating in the negotiation without direction from the committee.
In a recent opinion in In re Edgio, Inc. Stockholders Litigation, (Del. Ch.; 5/23), Vice Chancellor Zurn held that Corwin cleansing can’t apply to claims for post-closing injunctive relief under Unocal. Here are the facts of the case as summarized by this Cleary blog:
Limelight was approached by Apollo to discuss the potential combination of Limelight with Edgecast, Inc. (“Edgecast”). Edgecast’s parent company, College Parent, L.P. (“College Parent”), was owned approximately 90% by Apollo funds and 10% by Verizon Communications, Inc. Following a period of negotiation and due diligence, in March 2022, the parties executed a purchase agreement pursuant to which Limelight would acquire Edgecast in exchange for newly issued Limelight common stock, which would result in College Parent owning 35% of Limelight’s outstanding common stock after the closing of the transaction (the “Acquisition”). In connection with the Acquisition, the parties agreed on a form of stockholders’ agreement (the “Stockholders’ Agreement”) that would govern the terms of College Parent’s investment following the closing. Nasdaq listing rules required Limelight to obtain stockholder approval for the issuance of the stock consideration in the Acquisition. In advance of the vote, the Company issued a proxy statement that summarized the Acquisition and Stockholders’ Agreement (which was also publicly filed), including the provisions that would become the subject of the litigation. On June 9, 2022, the Company’s stockholders voted overwhelmingly in favor of the stock issuance. At closing of the Acquisition one week later, the parties entered into the Stockholders’ Agreement.
After the closing, two Company stockholders filed suit in Chancery Court against the Company and its Board of Directors (the “Board”), claiming the Stockholders’ Agreement included defensive measures that created a significant and enduring stockholder block designed to entrench the Board and shield it from stockholder activism.
Vice Chancellor Zurn denied the defendants’ motion to dismiss:
In reaching its decision, the Court found that certain voting commitments and transfer restrictions in a stockholders’ agreement between Limelight Networks, Inc. (n/k/a Edgio, Inc.) (“Limelight” or the “Company”) and its 35% stockholder were defensive measures that, at least for purposes of ruling on a motion to dismiss, it was reasonable to infer were implemented in order entrench Limelight’s directors against a perceived threat of shareholder activism. As a result, the Court reviewed the challenged provisions with enhanced scrutiny under Unocal.
. . .V.C. Zurn found that “a careful reading of Corwin’s text and other authorities compels the conclusion that Corwin was not intended to cleanse a claim to enjoin a defensive measure under Unocal enhanced scrutiny.” The Court pointed to language in Corwin itself, limiting its holding to post-closing damages claims, as reiterated by the Delaware Supreme Court in Morrison v. Berry. V.C. Zurn also noted that Corwin left untouched earlier Delaware Supreme Court precedent, In re Santa Fe, that appears to suggest a stockholder vote cannot cleanse claims for injunctive relief brought under Unocal. Finally, the Court asserted that applying Corwin to claims for injunctive relief would not serve Corwin’s underlying public policy rationale of allowing stockholders to make free and informed choices based on the economic merits of a transaction.
Wachtell Lipton recently published the 2023 edition of its 226-page “Distressed Investing, Mergers & Acquisitions” publication. Here’s how Wachtell describes the guide and its importance in the current environment:
As companies in the United States and abroad seek to manage the effects of rising interest rates, inflationary pressure, and economic uncertainty, increased financial distress may well emerge, along with opportunities for investment in distressed assets or businesses. The 2023 edition of our guide to Distressed Investing, Mergers & Acquisitions is designed to help investors and acquirors as they navigate the unique set of challenges, including the critical legal issues, associated with distressed situations. The guide covers topics ranging from acquisition of distressed debt claims and assets to strategies for obtaining control of troubled companies either in chapter 11 or out of court.
This guide and related resources are posted in our “Distressed Targets” Practice Area.
We recently blogged about the importance of both detailed diligence on a target’s compliance and addressing post-acquisition regulatory issues promptly and properly. In the wake of such a post-acquisition regulatory development, the opinion in LPPAS Representative, LLC v. ATH Holding Company, LLC, (Del. Ch.; 5/23) may have an impact on how buyers deal with regulators.
The case involved a common purchase agreement indemnification provision giving the indemnifying person the right to control the defense of third-party litigation—or to participate, in the case of a governmental regulator. After closing, Anthem, the buyer, discovered what it believed to be fraudulent Medicare coding practices at the target, promptly reported to CMS and DOJ and cooperated with the agencies without contacting sellers. When Anthem provided notice that it would be seeking indemnification, sellers claimed their participation rights were violated. Anthem tried to argue that they substantially complied and that failure to permit participation didn’t materially disadvantage sellers as they didn’t actually have a right to control the defense anyway. Chancellor McCormick disagreed and ordered that Anthem had abrogated any indemnity obligation by breaching the sellers’ participation rights.
This Fried Frank memo gives two practice pointers for any buyers of companies that regularly engage with regulatory authorities:
Before engaging with a regulator about a potential or actual investigation into pre-closing alleged issues, a buyer should carefully review its obligations under the sale agreement with respect to participation rights of the seller. Failure to provide the seller with the participation rights set forth in the sale agreement could affect, or even be fatal to, the buyer’s indemnification rights with respect to losses arising from the investigation.
Consideration should be given to modifying standard participation right provisions. Among the relevant considerations would be the respective negotiating leverage of the parties and the perceived level of risk that post-closing regulatory investigations might arise. Among the possible modifications would be: First, at a minimum, providing greater clarity and specificity as to the timing and extent of any right of the seller to participate in the defense strategy. For example, the parties may wish to specify more precisely than is typical the triggering event for the seller’s participation right—whether it is any inquiry from a regulator that could lead to an investigation; or the formal commencement of an investigation; or an investigation having proceeded to a specified point; or a specific claim having been formally asserted by the regulator. Second, a buyer may wish expressly to exclude specified actions from the participation rights—such as initial self-reporting of possible violations and responses to subpoenas or other legally required actions. Such modifications may be particularly appropriate in light of the DOJ’s and other regulators’ ongoing efforts to incentivize prompt self-reporting. Third, a buyer may wish to provide for its own participation rights with respect to the seller’s own, separate defense in connection with regulatory or criminal investigations of the seller’s pre-closing conduct.
There’s already been plenty of news coverage of the decision in City of Coral Springs Policy Officers’ Pension Plan v. Dorsey, (Del. Ch.; 5/23). But, for us lawyers, what @chancery_daily pointed out on Twitter and, of course, the news articles don’t is that this was really a demand futility case. I don’t blame the reporters for being swept up in the celebrity names and bad business decisions. Most importantly, Chancellor McCormick was not swayed by the bad facts, and so we have a fun read, and not bad law. Here’s the “quick” background:
Dorsey, founder, President and CEO of Block, is close friends with Jay-Z, who held a significant stake in TIDAL, a music streaming company, and had personally extended the company a $50 million loan. While the two friends were summering in the Hamptons, they chatted about Block (which had no existing intent to enter the music streaming industry) acquiring TIDAL and, while there, Dorsey joined a regular Block board meeting by video and raised the idea. The opinion details the resulting process, which involved forming a transaction committee, holding some meetings, lots of questions by the members, not so great answers, and ultimately the consummation of the deal at a reduced purchase price. Block’s stock dropped 7% on announcement.
Plaintiff stockholders filed a derivative suit, defendants moved to dismiss for failure to make a demand on the board, and the plaintiff stockholders argued futility. Chancellor McCormick assessed demand futility on a director-by-director basis under the Zuckerberg test, which assesses whether the director received a material personal benefit from the alleged misconduct, faces a substantial likelihood of liability or lacks independence from someone who received such a benefit or faces such likelihood. The demand would be excused if the answer to any question is yes for at least half of the board.
Since the company’s certificate contained an exculpation clause, to show a substantial likelihood of liability, plaintiff had to show that the directors were self-interested, beholden to an interested party or acted in bad faith. Six members of the board were independent, non-transaction committee members, for which Chancellor McCormick easily determined that their alleged failure to sufficiently supervise the transaction committee, even if true, was not bad faith. Dorsey, on the other hand, was clearly interested. With respect to the transaction committee defendants, the plaintiff tried to argue that Dorsey was basically pulling the deal forward singlehandedly and the transaction committee took an “ostrich-like” approach; even though they asked a lot of questions, “the answers did not seem to matter.”
Here’s an excerpt from the opinion:
Although the facts emphasized by Plaintiff do not generate tremendous confidence in the Transaction Committee’s process, they fall short of supporting an inference of bad faith. Effectively, Plaintiff asks the court to presume bad faith based on the merits of the deal alone. Plaintiff does not allege that the Transaction Committee lacked a business reason for wanting to acquire TIDAL—the presentation materials show management’s strategic goals for expanding Block into the music industry. Plaintiff does not attempt to allege that any of the Committee Defendants were in any way beholden to Dorsey. Plaintiff acknowledge that the Committee Defendants did not sit idly by while Dorsey presented. They asked many appropriate questions before the October 20 meeting, and they asked many appropriate follow-up questions in advance of the next meeting on January 22. The Transaction Committee were presented with over twenty single-spaced slides providing management’s detailed answers to each of these questions.
You can see that Chancellor McCormick sided with the defendants, but she also admitted that the deal “seemed, by all accounts, a terrible business decision.” Matt Levine summed this up as Chancellor McCormick saying “lol this was all ridiculous, but even so I’m going to allow it, because around here we defer to independent boards of directors.”
Deal Point Data recently released statistics on antitrust termination fees in public target deals where the target was headquartered in the US and the parties reached a definitive agreement from 2018 through April 18, 2023. They found:
– The percentage of deals with an antitrust termination fee was consistent between 2018 and 2020 but began to trend upward in 2021, with a significant increase to over 25% in 2023 to date
– The increase is greater when the data set is narrowed to deals with strategic buyers, with 31% of the deals in 2023 to date involving an antitrust termination fee
– Despite the increase in frequency, the size of antitrust termination fees has remained relatively consistent during the period surveyed
Michael Levin recently shared another UPC development – the second activist success story:
An individual investor, Daniel Mangless, owns 2.3% of Zevra Therapeutics (ZVRA), since 2019. Other than a few Form 13Gs for ZVRA and one other holding, the preliminary proxy statement for ZVRA was his first-ever SEC filing and, it appears, activist project.
He rather quietly nominated three candidates for three available seats on the seven-person classified BoD. ZVRA nominated the three incumbents, including the CEO and a director first appointed in November 2022. He also proposed reversing any bylaw amendments from 2023, which the ZVRA BoD could have approved but not disclosed to shareholders.
At the ASM last week, all three challengers won by a significant margin over the three incumbents. The bylaw amendment reversal also prevailed by a similar margin.
What’s a significant margin? All three activists won 80% of the votes cast, with the bylaw proposal passing with 84% of the vote. So, while UPC may have helped encourage the activist, it doesn’t appear to have impacted the outcome:
Shareholders didn’t see the need to split votes among incumbent and activist candidates, one of the features of UPC. All three challengers each received approximately the same votes, as did the three incumbents.
The other notable feature of this campaign was the activist’s particularly low expenses, estimated at $250,000.
John blogged earlier this year about the new statutory exemption for M&A Brokers from federal broker-dealer licensing requirements. In case you missed it, this K&L Gates blog reminds us that this statutory exemption became effective on March 29 and the SEC formally withdrew its 2014 no-action letter.
As John had noted, the exemption is limited to “eligible privately held companies,” which is defined as a company that has, in the fiscal year ending prior to the one in which the M&A broker is initially engaged: (i) no class of securities registered or required to be registered under §12 of the Exchange Act and (ii) EBITDA less than $25 million and/or gross revenues less than $250 million. This is a key departure from the no-action letter. Here’s an excerpt from this Morrison Foerster alert on why this creates complications:
Following adoption of the Act, while the No-Action Letter remained outstanding, private company M&A brokers could continue to rely on it for transactions involving larger private companies that did not fit within the limits set forth above. However, the SEC withdrew the No‑Action Letter on March 30, 2023, specifically citing the fact that the Act imposed size limitations not found in the No-Action Letter.
For many private company M&A advisers, the limitation on the size of eligible private companies will pose a major obstacle. We are in an era when more and more successful private companies decline to go public or postpone that decision to a later stage of their growth.[6] According to The New York Times, the number of public companies in the United States dropped by approximately 52% from the late 1990s to 2016.[7] As a result, the number of private companies that are larger than the caps permitted under the Act is likely to grow. M&A brokers servicing these companies now must register with the SEC as broker-dealers, even if they never engage in any other form of brokerage activity.
By contrast, M&A brokers who limit their involvement to the smaller “eligible” private companies will be entirely free of federal broker-dealer regulation. This stark difference may result in two different tiers of M&A boutiques, with some operating with limited or no regulatory oversight,[8] while those serving larger private companies will be subject to the extensive requirements of federal broker-dealer regulation. Some Congressional supporters of the Act argued that it was important to reduce the regulatory burden on brokers handling smaller deals in local communities. While that may be a worthwhile goal, it is not clear why brokers who, on occasion or on a regular basis, may advise larger private companies in M&A transactions and provide no other brokerage services should be subject to federal broker-dealer regulations that are equally ill-fitted to their business.
Since we’ve blogged in detail here about all the drama related to bylaw amendments following universal proxy, here’s Liz’s post on the Proxy Season blog on TheCorporateCounsel.net related “fair elections” shareholder proposals:
In the wake of the SEC’s universal proxy card rules, some companies have been testing the limits on advance notice bylaws. If you go too far, you not only risk alienating your investors – you may also have to defend yourself in court. Meredith blogged about some of that back & forth last month.
Another consideration here is that this is a “hot topic” for shareholder proponents who are focused on corporate governance. Late last year, Jim McRitchie submitted this “fair elections” proposal to approximately 30 companies:
James McRitchie and other shareholders request that directors of [____] (“Company”) amend its bylaws to include the following language:
Shareholder approval is required for any advance notice bylaw amendments that:
1. require the nomination of candidates more than 90 days before the annual meeting,
2. impose new disclosure requirements for director nominees, including disclosures related to past and future plans, or
3. require nominating shareholders to disclose limited partners or business associates, except to the extent such investors own more than 5% of the Company’s shares.
A few of these proposals are currently expected to go to a vote in the upcoming weeks. Jim noted in a recent update that he’s also withdrawn several proposals – in exchange for an agreement from the company to add the following language to the corporate governance guidelines:
The Board is committed to providing a director nomination process that is fair and equitable to all nominating shareholders, and as such the Board will not, without shareholder consent, adopt any amendments to the Bylaws of the Company that would expressly (1) require nominating stockholders that are investment funds or other investment vehicles to disclose the identities of less than five percent stockholders, members, limited partners or holders of similar economic interests solely on account of such holders’ economic interests (so long as such holders do not have or share control over the nominating stockholder and are not participating in the stockholder’s solicitation of proxies), (2) require nominating stockholders to disclose plans to nominate candidates to the board of directors of other public companies, or (3) require nominating stockholders to disclose prior stockholder proposals or director nominations that such a stockholder privately submitted to other public companies.
If the Board, in its exercise of its fiduciary responsibilities, deems it to be in the best interests of the Company’s stockholders to adopt such provision without the delay that would come from the time reasonably anticipated to seek such a stockholder vote, the Board will either submit the advance notice bylaw to stockholders for ratification or cause the advance notice bylaw to expire within one year.
In this LinkedIn post, Jim also previews that he plans to reword this proposal to protect against no-action challenges, and recirculate it next year. Since it is often challenging to gather enough shareholders to pay attention to a bylaw amendment, if you are considering updating your advance notice bylaw, this may be a reason to take a look at it sooner rather than later.